Who owns the patent for EpiPen?

In March 2008, Sciele Pharma acquired Twinject from Verus and later that year, Sciele was acquired by Shionogi. In 2007, Mylan acquired the right to market the EpiPen from Merck KGaA as part of a larger transaction. At that time annual sales were around $200 million and the EpiPen had about 90% of the market.

What is the difference between anapen and EpiPen?

Anapen requires a different administration technique to that of EpiPen. The Anapen autoinjector is triggered by depressing a red button with the thumb, whereas the EpiPen device is held mid-section — with the thumb and fingers forming a fist — and triggered by pressing firmly into the outer mid-thigh (Figure 1).

How does a JEXT pen work?

Jext auto-injection pens contain the active ingredient adrenaline, which is a hormone produced naturally by the body. Adrenaline is usually released by the adrenal glands in times of stress. It prepares the body when extra energy or exertion is needed, making the body more able to deal with life-threatening situations.

Is there a monopoly on EpiPen?

With the help of these laws, Mylan’s EpiPens are at 63,000 schools nationwide and the company has distributed 500,000 of them for free through EpiPens4Schools. Mylan also has a virtual monopoly on epinephrine auto-injectors simply because there are almost no other products like it, either branded or generic.

When did the EpiPen patent expire?

2025
Its four EpiPen patents do not expire until 2025.

Who can administer an Anapen?

They are designed to administer a single, fixed dose of adrenaline and can be given by anyone, including people who are not medically trained. There are two different brands of adrenaline autoinjector available in Australia; EpiPen and Anapen.

Who makes Anapen?

Anapen® contains a pre-filled adrenaline (epinephrine) syringe in an intuitive auto-injection device (auto-injector) manufactured by Bioprojet Pharma, Europe.